Mankind Pharma Ltd. Financials: Quarterly Results
Revenue
3330.7
Cr.
PAT
426.67
Cr.
EBITDA
703.65
Cr.
Mankind Pharma Ltd. Q4FY25 Financial Metrics
| Indicator | Mar-25 | Dec-24 | Sep-24 | Jun-24 | Mar-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 3079.37 | 3230 | 3076.51 | 2893.42 | 2441.10 |
| Total Income From Operations (Cr.) | 3079.37 | 3230 | 3076.51 | 2893.42 | 2441.10 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 703.65 | 714.82 | 853.85 | 674.62 | 578.54 |
| P/L Before Exceptional Items & Tax (Cr.) | 513.11 | 493.89 | 846.75 | 663.71 | 569.16 |
| P/L After Tax from Ordinary Activities (Cr.) | 426.67 | 381.08 | 656.31 | 539.16 | 474.18 |
| Net Profit/Loss For the Period (Cr.) | 422.33 | 381.08 | 656.31 | 539.16 | 474.18 |
| Basic EPS | 10.20 | 9.45 | 16.31 | 13.39 | 11.76 |
FAQs
Mankind Pharma Ltd. announced its quarterly results for Q4 FY2025 on May 21, 2025.
In Q4 FY2025, Mankind Pharma Ltd. are as follows:
Revenue: ₹3330.7 crore
Net Profit: ₹422.33 crore.
For Q4 FY2025, Mankind Pharma Ltd. posted ₹3330.7 crore in revenue and ₹422.33 crore in net profit.
Past quarterly results for Mankind Pharma Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.